Case Report: Ustekinumab for Crohn's Continued in Pregnancy

Share this content:
Case Report: Ustekinumab for Crohn's Continued in Pregnancy
Case Report: Ustekinumab for Crohn's Continued in Pregnancy

WEDNESDAY, Dec. 28, 2016 (HealthDay News) -- Good outcome has been reported in a pregnant woman who continued ustekinumab (UST) therapy for Crohn's disease during pregnancy, according to a case report published online Dec. 22 in the Journal of Clinical Pharmacy and Therapeutics.

Xavier Cortes, M.D., from the Hospital de Sagunto in Spain, and colleagues describe the case of a pregnant patient with Crohn's disease who was successfully treated with UST maintenance therapy during pregnancy. The 37-year-old patient had been receiving UST for eight months before becoming pregnant. She continued UST treatment after discussion with the obstetric team.

The authors note that the patient had an uneventful pregnancy and delivered a healthy baby boy at term. The patient was in clinical and biological remission during pregnancy and was still in clinical, biological, and endoscopic remission six months after delivery. No side effects were reported during UST therapy, with no recurrent episodes and no reports of problems for the baby at one-year follow-up.

"To our knowledge, this is the first reported use of continued UST therapy for Crohn's disease throughout a pregnancy," the authors write. "The result of treatment was an uncomplicated pregnancy with the mother giving birth to a healthy boy at term and the maintenance of clinical biological and endoscopic remission of Crohn's disease during and after pregnancy."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »